Lilly taps Shaquille O'Neal for national Zepbound sleep apnea campaign

Eli Lilly and Company announced on June 10, 2026 that basketball legend Shaquille O'Neal is the face of a national campaign called Watch This, built around his own diagnosis of moderate obstructive sleep apnea and his prescription for Zepbound (tirzepatide) ^[1]. The push runs across broadcast, streaming, digital and social channels, along with community events and in-person appearances ^[1].

O'Neal, 54 ^[2], described years of writing off his symptoms. "For a long time, I was tired during the day, snoring and gasping for air at night, and I just thought that's how it was for someone like me," he said in a Q&A released with the announcement ^[1]. Once a doctor named the condition, he said, the picture became clearer - "this wasn't just about snoring, it was a real health condition" ^[1]. He added that being prescribed Zepbound made a difference in his treatment and that he "even lost some weight" ^[1].

Lilly is framing the ads around the sleep disorder itself rather than weight. The company says roughly 24 million American adults have moderate-to-severe OSA, many of them also living with obesity, and that 85% of those cases have never been diagnosed ^[1]. Loud snoring, daytime fatigue and difficulty concentrating are among the signs the announcement lists ^[1].

Two 52-week Lilly studies are cited in the release. In the first, volunteers taking 10 mg or 15 mg of Zepbound cut their average apnea-hypopnea index from 52.9 breathing disruptions per hour of sleep to 27.6, while the placebo group moved from 50.1 to 44.8 ^[1]. In the second, which enrolled people already using positive airway pressure (PAP) therapy, the treated group fell from 46.1 to 16.8 events per hour, compared with 53.1 to 47.6 on placebo ^[1]. Lilly also reported that 42.2% of the Zepbound group in the first trial and 50.2% in the PAP trial reached either an AHI below 5 or an AHI of 5 to 14 paired with an Epworth Sleepiness Scale score of 10 or lower, versus 15.9% and 14.3% on placebo ^[1].

The approved use is narrower than the campaign's reach. Zepbound is cleared for adults who have both moderate-to-severe OSA and obesity, and it is meant to be used with a reduced-calorie diet and more physical activity ^[1]. Lilly calls it the only prescription medicine approved for that purpose ^[1]. The label carries a warning about thyroid tumors, including thyroid cancer; the drug is not for people with a personal or family history of medullary thyroid carcinoma, with MEN 2, or with a prior serious allergic reaction to tirzepatide ^[1]. Serious side effects listed include severe stomach problems, dehydration that can lead to kidney problems, gallbladder disease and pancreatitis ^[1]. Lilly says Zepbound should not be combined with another tirzepatide product or any GLP-1 receptor agonist, and that its safety and effectiveness in children are not known ^[1].

Why it matters for patients

If most moderate-to-severe OSA really does go unrecognized ^[1], then for people who snore heavily or feel drained during the day, the first move toward care may be raising the subject themselves. Lilly's consumer marketing chief, Lina Polimeni, said O'Neal "didn't simply want to be another name on a campaign - he wanted to tell the truth about his own health on his own terms" ^[1].

The medication's approved use is limited to adults with obesity as well as sleep apnea; patients with OSA who do not have obesity fall outside the indication described in the announcement ^[1]. In the PAP study, participants kept using their machines while taking the drug, and nothing in the release suggests Zepbound replaces PAP therapy ^[1]. The figures describe group averages over a year, not what any single patient can expect ^[1].

Cost and coverage are not addressed. No price appears in the release, and no insurers are named as covering Zepbound specifically for sleep apnea; Lilly instead points readers to a company savings page ^[1]. Also not disclosed: how long O'Neal has taken the drug, how much weight he lost, and how severe his apnea measured on a sleep study ^[1]. Everyday Health, in a roundup of celebrities who have discussed GLP-1 drugs, notes his June 2026 disclosure and repeats his statement ^[2].

What happens next

The campaign was already under way when it was announced ^[1]. Lilly has not published an end date, a budget or a schedule of the community appearances ^[1]. The company directs people who think they may have OSA symptoms to Lilly.com, where it says they can learn about at-home testing or talk with a doctor about treatment options ^[1].